Pullen Investment Management LLC bought a new position in shares of Humana Inc. (NYSE:HUM – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,009 shares of the insurance provider’s stock, valued at approximately $348,000.
A number of other large investors also recently modified their holdings of HUM. Hsbc Holdings PLC boosted its holdings in shares of Humana by 9.1% in the 4th quarter. Hsbc Holdings PLC now owns 330,794 shares of the insurance provider’s stock valued at $85,107,000 after buying an additional 27,530 shares during the period. Reflection Asset Management acquired a new stake in Humana during the fourth quarter worth about $29,000. Invesco Ltd. raised its stake in Humana by 9.3% during the fourth quarter. Invesco Ltd. now owns 2,233,130 shares of the insurance provider’s stock worth $571,972,000 after acquiring an additional 189,670 shares during the period. Corient Private Wealth LLC lifted its holdings in Humana by 329.3% in the fourth quarter. Corient Private Wealth LLC now owns 120,104 shares of the insurance provider’s stock worth $30,762,000 after acquiring an additional 92,125 shares during the last quarter. Finally, Ameriflex Group Inc. bought a new position in Humana in the fourth quarter worth about $128,000. 92.38% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have commented on HUM. JPMorgan Chase & Co. lifted their target price on Humana from $214.00 to $316.00 and gave the company a “neutral” rating in a research note on Monday, June 8th. Seaport Research Partners cut Humana to a “neutral” rating in a research report on Wednesday, May 20th. Zacks Research raised Humana from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 13th. Sanford C. Bernstein restated an “outperform” rating and set a $425.00 price objective on shares of Humana in a research report on Wednesday, June 3rd. Finally, Bank of America upped their price objective on Humana from $267.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $291.35.
Humana Price Performance
Shares of NYSE HUM opened at $360.84 on Friday. The stock has a market cap of $43.32 billion, a P/E ratio of 38.59, a P/E/G ratio of 2.05 and a beta of 0.76. The firm’s 50-day simple moving average is $285.88 and its 200 day simple moving average is $241.60. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $380.86. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66.
Humana (NYSE:HUM – Get Free Report) last announced its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The firm had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. Humana’s revenue was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts expect that Humana Inc. will post 9.04 EPS for the current year.
Humana Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.0%. Humana’s dividend payout ratio (DPR) is 37.86%.
About Humana
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Read More
- Five stocks we like better than Humana
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
